A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler® 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis® Turbuhaler® 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease
A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler® 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis® Turbuhaler® 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
Inclusion Criteria:
Exclusion Criteria:
Toyota-shi, Aichi-ken, Japan
Takayama-shi, Gifu, Japan
Naka-gun, Ibaragi, Japan
Kawasaki-shi, Kanagawa, Japan
Zama-shi, Kanagawa, Japan
Matsusaka-shi, Mie-ken, Japan
Chino-shi, Nagano, Japan
Isahaya-shi, Nagasaki, Japan
Saiki-shi, Oita Prefecture, Japan
Yufu-shi, Oita Prefecture, Japan
Kurashiki-shi, Okayama-ken, Japan
Urasoe-shi, Okinawa, Japan
Izumi-shi, Osaka, Japan
Sakai-shi, Osaka, Japan
Kitakatsushika-gun, Saitama, Japan
Koshigaya-shi, Saitama, Japan
Itabashi-ku, Tokyo, Japan
Minato-ku, Tokyo, Japan
Shinagawa-ku, Tokyo, Japan
Suginami-ku, Tokyo, Japan
Sumida-ku, Tokyo, Japan
Lipa City, Batangas, Philippines
Loma, Poland
Vinytsa, Ukraine
Zaporozye, Ukraine